

I. Amendments to the Claims Pursuant to 37 C.F.R. § 1.121 (c)

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended.) A pharmaceutical and/or cosmetic product comprising first and second ~~emulsion active ingredient containing~~ formulations for topical administration to the skin, hair or nails of a mammal, each of said formulations containing an aqueous phase and a non-aqueous phase, and at least one of each of said phases containing at least one active ingredient, wherein said product includes storage means whereby said formulations are maintained separately prior to dispense, together with dispense means which permit said formulations to be dispensed from said storage means, characterised in that (i) ~~an active ingredient in~~ at least one of said formulations contains is contained within a polymeric delivery system comprised of polymers capable of entrapping and controlling the release of the at least one active ingredient and (ii) both of said formulations comprise water-based carrier bases having substantially the same lipophilicity and (iii) the viscosities of each of said formulations is less than about 25,000 centipoise.
2. (Currently amended.) A pharmaceutical and/or cosmetic product according to claim 1 wherein the polymeric delivery system is non-swellable and cross-linked ~~said formulations each comprise aqueous carrier bases.~~
3. (Currently amended.) A pharmaceutical and/or cosmetic product according to claim 2 wherein the polymeric delivery system is selected from the group consisting of (a) solid microporous micro-particle copolymers of allyl methacrylate and ethylene glycol dimethacrylate, (b) compounds made by suspension polymerization of lauryl methacrylate and ethylene glycol dimethacrylate using a peroxide as a catalyst and (c) solid particles composed of a cross-linked copolymer of monoethylenically unsaturated monomers and polyethylenically unsaturated monomers and having a cross-linking density from 20% to 80%, wherein said particles contain a continuous noncollapsible network of pores open to the exterior of said particles, are substantially spherical in shape, and have an average diameter of about 1 micron to about 100 microns, a total pore volume of about 0.01 cc/g to about 4.0 cc/g, a surface area of

about 1 m²/g to about 500 m²/g, and an average pore diameter of about 0.001 micron to about 3.0 microns ~~comprised of a plurality of crosslinked porous polymer particles forming a porous polymeric matrix in which the at least one active ingredient is entrapped.~~

4. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the dispense means are such as to permit dispense of the first formulation in a specific ratio to the second formulation.
5. (Currently amended.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the storage means comprise side-by-side chambers each equipped with a dispense valve, said valves being operable by a single actuator or by adjacently disposed actuators.
6. (Currently amended.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the storage means comprises a unit dose pouch having separate parts for each formulation.
7. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the dispense means are adapted to dispense said formulations separately.
8. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the first formulation is an aqueous topical cream or gel carrier base containing an antibacterial and/or keratolytic agent incorporated into a polymeric delivery system and the second formulation is an aqueous carrier base having substantially the same lipophilicity as the first formulation and containing a topical antibiotic.
9. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 8 wherein said keratolytic agent is a retinoid.
10. (Currently amended.) A pharmaceutical and/or cosmetic product according to claim 9 wherein the retinoid is selected from the group consisting of retinol, retinoic acid, tazarotene and adapalene.

11. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 8 wherein the antibacterial agent is salicylic acid or an organic peroxide.
12. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 11 wherein said organic peroxide is benzoyl peroxide.
13. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 8 wherein the antibacterial and/or keratolytic agent incorporated into a polymeric delivery system is selected from the group consisting of retinoids, salicylic acid and organic peroxides and ~~said~~ the antibiotic is selected from the group consisting of erythromycin, clindamycin or a tetracycline.
14. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 13 wherein the antibacterial and/or keratolytic agent is benzoyl peroxide and the topical antibiotic is clindamycin.
15. (Canceled.)
16. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 which comprises as active ingredients an anti-fungal agent and a retinoid, at least one of which is incorporated into a polymeric delivery system.
17. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 16 wherein the anti-fungal agent is selected from the group consisting of undecilenic acid, miconazole, in the form of a base or nitrate, ketoconazole, iconazole, clotrimazole and the retinoid is either retinol or retinoic acid.
18. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 which comprises as active ingredients a depigmenting agent and a keratolytic agent, at least one of which is incorporated into a polymeric delivery system.
19. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 which comprises as active ingredients a depigmenting agent and a retinoid, at least one of which is incorporated into a polymeric delivery system.

20. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 19 which further comprises a corticosteroid.
21. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 which comprises as active ingredients a corticosteroid and a retinoid at least one of which is incorporated into a polymeric delivery system.
22. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 which comprises as active ingredients a hair growth promoter and a retinoid or other keratolytic agent, at least one of which is incorporated into a polymeric delivery system.
23. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 1 wherein said first and second formulations have substantially the same water content.
24. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 1 wherein said first and second formulations have substantially the same viscosity.
25. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 1 comprising more than two active ingredient-containing formulations for topical administration to the skin, hair or nails of a mammal, together with storage means whereby each of said formulations is separately maintained prior to dispense, wherein (i) an active ingredient in at least one of said formulations is contained within a polymeric delivery system comprised of a plurality of crosslinked porous polymer particles forming a porous polymeric matrix in which is contained an active ingredient and (ii) all of said formulations comprise water-based carrier bases having substantially the same lipophilicity.
26. (Previously amended.) A pharmaceutical and/or cosmetic product according to claim 3 which comprises a dual or multi-chamber dispense system having an actuator which causes dispense of said formulations from one or more orifices and a closure

which (i) prevents depression of the actuator or (ii) covers or seals the orifice(s) of the dispense system.

27. (Canceled.)

28. (Canceled.)

29. (Canceled without prejudice.)

30. (Canceled without prejudice.)

31. (Previously presented.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the first and second active ingredient-containing formulations each has a viscosity of less than about 20,000 cps.

32. (Previously presented.) A pharmaceutical and/or cosmetic product according to claim 3 wherein the first and second active ingredient-containing formulations each has a viscosity of less than about 10,000 cps.

33. (Previously presented.) A pharmaceutical and/or cosmetic product according to claim 1 wherein the lipophilicities of the first and second active ingredient-containing formulations vary by no more than 10%.

34. (Previously presented.) A pharmaceutical and/or cosmetic product according to claim 1 wherein the lipophilicities of the first and second active ingredient-containing formulations vary by no more than 5%.

35. (Previously presented.) A pharmaceutical and/or cosmetic product according to claim 1 wherein the lipophilicities of the first and second active ingredient-containing formulations vary by no more than 2.5%.